Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Crucell« Terug naar discussie overzicht

J&J neemt cru over

73 Posts
Pagina: 1 2 3 4 »» | Laatste | Omlaag ↓
  1. eddy59 31 oktober 2009 09:08
    12:13 EDT GSK theflyonthewall.com: Human Genome to announce new trial results Monday, analysts optimistic

    Subscribe for More Information :theflyonthewall.com

    11:53 EDT CRXL theflyonthewall.com: Crucell NV calls active on renewed buyout chatter into EPS

    Subscribe for More Information :theflyonthewall.com

    11:37 EDT JNJ theflyonthewall.com: Johnson & Johnson management to meet with JP Morgan

    Subscribe for More Information :theflyonthewall.com

    10:52 EDT CRXL theflyonthewall.com: Rumor: Crucell moves up on renewed takeover speculation
    :theflyonthewall.com

    08:13 EDT VRX theflyonthewall.com: Valeant to acquire Polish prescription, cosmetic dermatology products



  2. [verwijderd] 31 oktober 2009 09:12
    News Breaks
    12:15 EDT CRXL, OSIP, JNJ, GSK, VRX theflyonthewall.com: TheFly's Rumor Round-Up
    A few names have moved this morning due to market speculation. OSI Pharmaceuticals (OSIP) traded higher on renewed takeover chatter that GlaxoSmithKline (GSK) is eyeing the company in the low-to-mid $40 per share range. Earlier in October, Glaxo was rumored to be interested in Valeant Pharmaceuticals (VRX) and the U.K.'s SSL International. Glaxo seems to have run out of ideas, its pipeline is dry, and trading desks speculate that some takeover ideas would represent a solution to help its portfolio. Also in health care, Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share. On September 28 the companies announced that J&J, through its Ortho-McNeil-Janssen Pharmaceuticals subsidiary, and Crucell, had entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines. :theflyonthewall.com

  3. eddy59 31 oktober 2009 09:17
    quote:

    balletent schreef:

    News Breaks
    12:15 EDT CRXL, OSIP, JNJ, GSK, VRX theflyonthewall.com: TheFly's Rumor Round-Up
    A few names have moved this morning due to market speculation. OSI Pharmaceuticals (OSIP) traded higher on renewed takeover chatter that GlaxoSmithKline (GSK) is eyeing the company in the low-to-mid $40 per share range. Earlier in October, Glaxo was rumored to be interested in Valeant Pharmaceuticals (VRX) and the U.K.'s SSL International. Glaxo seems to have run out of ideas, its pipeline is dry, and trading desks speculate that some takeover ideas would represent a solution to help its portfolio. Also in health care, Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share. On September 28 the companies announced that J&J, through its Ortho-McNeil-Janssen Pharmaceuticals subsidiary, and Crucell, had entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines. :theflyonthewall.com


    Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share

    Waar kunnen we zien dat its trading higher????
    US was lower.
    After hours?????
    Calls ???

  4. aossa 31 oktober 2009 09:20
    quote:

    eddy59 schreef:

    [quote=balletent]
    News Breaks
    12:15 EDT CRXL, OSIP, JNJ, GSK, VRX theflyonthewall.com: TheFly's Rumor Round-Up
    A few names have moved this morning due to market speculation. OSI Pharmaceuticals (OSIP) traded higher on renewed takeover chatter that GlaxoSmithKline (GSK) is eyeing the company in the low-to-mid $40 per share range. Earlier in October, Glaxo was rumored to be interested in Valeant Pharmaceuticals (VRX) and the U.K.'s SSL International. Glaxo seems to have run out of ideas, its pipeline is dry, and trading desks speculate that some takeover ideas would represent a solution to help its portfolio. Also in health care, Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share. On September 28 the companies announced that J&J, through its Ortho-McNeil-Janssen Pharmaceuticals subsidiary, and Crucell, had entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines. :theflyonthewall.com


    [/quote]
    Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share

    Waar kunnen we zien dat its trading higher????
    US was lower.
    After hours?????
    Calls ???
    Ze kijken in hun glazen bol... (maandag hoger dus).
  5. maxen 31 oktober 2009 09:49
    quote:

    eddy59 schreef:

    ...
    Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share

    Waar kunnen we zien dat its trading higher????
    US was lower.
    After hours?????
    Calls ???
    't Was slechts een spike-je op Nasdaq en AEX. Daarna alweer lager. Dus wellicht een kunstmatig bericht/gerucht , tezamen met een serieuze aankoop, om snel wat met opties te rommelen (bv om met beperkt verlies wat calls te verkopen). Als er ergens een spike-je met volume wordt gezien, volgen de koopcomputers (en daarna traders) snel, onder het motto 'waar rook is, is vuur'. Als het momentum niet doorzet, verkopen ze weer.

    Omdat het NA het spike-je nog 5 uur vrij rustig was voor Crucell Nasdaq pps en omzet lijkt het me sterk dat er meer achter zat. Komt nog bij: De aard van het gerucht. Volgens mij is een volledige overname door J&J niet zozeer tegen de letter alswel tegen de geest van de overeenkomst:

    "In connection with the equity investment, Crucell and JHC Nederland have entered into a shareholder agreement setting forth certain rights and restrictions of JHC Nederland as a shareholder, which includes a 3-year standstill requiring Crucell's consent for an increase of JHC Nederland's interest in Crucell (subject to customary exceptions)"

    Maar je weet het nooit, ALS er overname-nieuws (van of door Crucell) van Crucell komt is dat inderdaad 't meest waarschijnlijkst op maandag. Dat maakt overigens ook het opzettelijk verspreiden van geruchten op vrijdag het geloofwaardigst.

    P.S.
    En '%28' komt gewoon van het afbreken van een link, en heeft niets met 28% toename in Crucell pps te maken :-)
  6. aossa 31 oktober 2009 11:27
    '1.000 jobs in gevaar bij Janssen Pharmaceutica'

    Bij Janssen sneuvelden eerder al jobs

    Bij Janssen Pharmaceutica, de parel van de Vlaamse farma-industrie, dreigt opnieuw een drastische herstructurering. Dinsdag staat een Europese ondernemingsraad op de agenda en de vakbonden vrezen dat de hakbijl dan weer bovengehaald zal worden.

    (belga) - Dat meldt Het Laatste Nieuws zaterdag.

    "Er circuleren cijfers van 100 tot 1.000 afvloeiingen in België", zegt LBC-afgevaardigde Frans Geerts. De directie wil de plannen niet bevestigen.

    Op de site in Beerse, bij Turnhout, heerst een zenuwachtige stemming. Al weken circuleren geruchten dat Janssen Pharmaceutica aan de vooravond van een nieuwe, grondige sanering staat. Het zou de derde zijn in haast evenveel jaar, want in 2007 verdwenen al 600 banen, en vorig jaar sneuvelden nog eens 140 jobs. Momenteel werken bij de farmagroep nog zo'n 4.200 mensen, onder wie 800 hoogopgeleide onderzoekers.
  7. [verwijderd] 31 oktober 2009 13:23
    quote:

    aossa schreef:

    [quote=eddy59]
    [quote=balletent]
    News Breaks
    12:15 EDT CRXL, OSIP, JNJ, GSK, VRX theflyonthewall.com: TheFly's Rumor Round-Up
    A few names have moved this morning due to market speculation. OSI Pharmaceuticals (OSIP) traded higher on renewed takeover chatter that GlaxoSmithKline (GSK) is eyeing the company in the low-to-mid $40 per share range. Earlier in October, Glaxo was rumored to be interested in Valeant Pharmaceuticals (VRX) and the U.K.'s SSL International. Glaxo seems to have run out of ideas, its pipeline is dry, and trading desks speculate that some takeover ideas would represent a solution to help its portfolio. Also in health care, Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share. On September 28 the companies announced that J&J, through its Ortho-McNeil-Janssen Pharmaceuticals subsidiary, and Crucell, had entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines. :theflyonthewall.com


    [/quote]
    Crucell (CRXL) is trading higher on speculation that Johnson & Johnson (JNJ) will acquire it at $32 per share

    Waar kunnen we zien dat its trading higher????
    US was lower.
    After hours?????
    Calls ???[/quote]
    Ze kijken in hun glazen bol... (maandag hoger dus).
    If only it were true! I'll take the $32 in a heartbeat,,,if they only promise to fire Brus.

    Stock is going nowhere for at least three years...

    No afterhours trading in the US.
73 Posts
Pagina: 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.